 |
|
|
|
 |
|
|
| Article 1 to 10 out of 27 concerning Akzo Nobel nv
|
-
Akzo Nobel completes OBS sale
(21 Nov 2007)
Akzo Nobel N.V. has completed the sale of Organon BioSciences N.V. to Schering-Plough Corporation for EUR 11 billion. Confirmation of the completion of the transaction comes after Schering-Plough received all the necessary approvals, including ...
-
Organon signs an exclusive, worldwide licence agreement on advanced antithrombotic compounds with Endotis Pharma
(02 Nov 2007)
Organon, the human healthcare business unit of Akzo Nobel, announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a ...
-
European expert consortium combines forces to develop a novel pandemic influenza vaccine
(28 Sep 2007)
A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 ...
-
Xceleron and Organon sign microdose study agreement
(12 Sep 2007)
Xceleron Ltd announced a collaboration with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development. Xceleron has been selected by Organon ...
-
Organon and MRC Technology sign antibody development agreement
(26 Jul 2007)
Organon, the human healthcare business unit of Akzo Nobel, together with MRC Technology announced that they have signed a collaborative agreement to develop a humanized antibody for the treatment of certain forms of cancer. The Therapeutic Antibody ...
-
Organon announces acquisition of Kadmus Pharmaceuticals' FAAH inhibitor technology
(28 Jun 2007)
N.V. Organon, the human healthcare business unit of Akzo Nobel, announced an asset purchase of the Fatty Acid Amide Hydrolase (FAAH) technology from Kadmus Pharmaceuticals, Inc. in Irvine CA (USA).Under the asset purchase agreement, Organon has ...
-
Nobilon acquires rights to EBx cell lines from Vivalis for development, production and marketing of influenza vaccines
(01 Jun 2007)
Nobilon and Vivalis announced that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx® cell lines (derived from avian embryonic stem cells) and related technology platform for the ...
-
Organon and Philips team up to study drug effects at the molecular level
(25 May 2007)
N.V. Organon, the human health care business unit of Akzo Nobel, and Royal Philips Electronics announced that they will join forces in the development of new drugs and therapies for mental disorders and cancer. With the help of biomarkers and ...
-
Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment
(22 May 2007)
Organon announced that it has now completed recruitment for both pivotal phase IIIa trials for NOMAC/E2, its novel oral contraceptive containing natural estrogen. According to the company, the success means the development program is on track for ...
-
Organon and Medarex announce biotherapeutics development agreement
(21 May 2007)
Organon, the human health care business unit of Akzo Nobel, and Medarex, Inc. announced that they have entered into a collaborative agreement to develop and potentially commercialize fully human antibody therapeutics for the treatment of cancer and ...
|
|
|
|
|
Top
